•1992 : PhD in Medicinal Chemistry, University Louis Pasteur, Strasbourg.
•1999: Habilitation to supervise research (HDR), University Louis Pasteur, Strasbourg, France.
•2012: Certification in Translational Oncology, EPHE, Dijon, France.
Faculty positions

•2014-present: CNRS research director (DR2) at the University of Strasbourg, and since 2015, Visiting Professor at Tianjin University of Science and Technology (TUST) in China in the Sino-French Joint Lab of Nutrition and Medicinal Chemistry headed by Professor Peng Yu.

•2005-2014: CNRS senior scientist (CR1) at the University of Strasbourg.

•1998-2004 : postdoctoral associate and thereafter CNRS research senior scientist (CR1) in the laboratory of Prs Guy Ourisson and Yoichi Nakatani in Louis Pasteur University, Strasbourg.

•1997-1998 : postdoctoral associate in the laboratory of Pr Pierre Chambon and Dr Heinrich Gronemeyer at IGBMC, Strasbourg-Illkirch.

•1992-1996: postdoctoral associate in Pr Roger A. Johnson’s laboratory, Department of Physiology and Biophysics, State University of New York at Stony Brook, USA.

ORCID: 0000-0002-1192-2970

Editorial Board membership

Frontiers in Chemistry, Medicinal Chemistry, Journal of Oncology Research and Treatments, Current Chinese Chemistry and International Journal of Molecular Science.

Research Focus

New cardioprotective non-peptide agonists of prokineticin receptor 1 (PKR1)

Cardiac dysfunction leading to heart failure can result from anticancer treatments. As a member of the European ERA-NET consortium in Cardio-Oncology, we are developing new PKR1 agonists to protect the heart against these adverse effects.

Publications on PKR1 agonists

Anticancer eIF4A inhibitors

The helicase eiF4A belongs to the eIF4F complex that regulates cap-dependent mRNA translation and represents an emerging target in oncology. An aberrant activity of this complex is observed in many cancers, contributing to resistance to cancer treatments. We are developing new eIF4A to treat cancers resistant to chemotherapies, targeted therapies and immune checkpoint inhibitors.

Publications on eIF4A inhibitors

Prohibitins modulators

Prohibitins-1 and -2 (PHB1 and PHB2) are scaffold that regulate many signaling proteins. With our collaborators, we are currently developing several classes of prohibitin ligands against cancers, the adverse effects of anticancer treatments and immune disorders.

Publications on prohibitins modulators

Organic chemistry

As part of our projects, we have to develop new reactions in organic synthesis. In each instance, the methodology development represents the investigation of chemistry projected as a key step in the synthesis of new drugs related to the projects presented above.

Publications in organic chemistry

Other publications